Deucravacitinib + Placebo

Phase 2Withdrawn

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Papulopustular Rosacea

Conditions

Papulopustular Rosacea

Trial Timeline

Nov 1, 2024 → Jan 1, 2026

NCT ID

NCT06532136

About Deucravacitinib + Placebo

Deucravacitinib + Placebo is a phase 2 stage product being developed by Bristol Myers Squibb for Papulopustular Rosacea. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT06532136. Target conditions include Papulopustular Rosacea.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06532136	Phase 2	Withdrawn	Nov 1, 2024	Jan 1, 2026	Papulopustular Rosacea
NCT05997277	Phase 2	Terminated	Nov 30, 2023	Apr 10, 2025	Hidradenitis Suppurativa
NCT06042920	Approved	Terminated	Oct 9, 2023	Apr 25, 2025	Palmoplantar Psoriasis
NCT04857034	Phase 2	Active	Jul 12, 2021	Feb 28, 2028	Lupus Erythematosus, Discoid

Competing Products

18 competing products in Papulopustular Rosacea

See all competitors

Product	Company	Stage	Hype Score
Lotilaner Gel, 2.0%	Tarsus Pharmaceuticals	Phase 2	47
Topical Dapsone 5% Gel + oral antibiotics	Bristol Myers Squibb	Phase 3	76
Azelaic acid (Finacea, BAY39-6251) + Metronidazole (Metrogel) + Doxycycline (Oracea)	Bayer	Approved	82
Azelaic Acid foam 15%	Bayer	Approved	82
Azelaic acid + Vehicle foam	Bayer	Phase 2	49
Azelaic acid foam 15% + Vehicle foam	Bayer	Phase 2	49
azelaic acid 15% gel + azelaic acid 15% gel	Bayer	Approved	82
Azelaic Acid Foam + Azelaic Acid Gel	Bayer	Phase 1	30
Azelaic acid foam, 15% (BAY39-6251) + Vehicle foam	Bayer	Phase 3	74
DFD-29 + Doxycycline + Placebo	Dr. Reddy's Laboratories	Phase 3	74
DFD-29 + Doxycycline + Placebo	Dr. Reddy's Laboratories	Phase 3	74
Encapsulated Benzoyl Peroxide Cream	Sol-Gel Technologies	Phase 1	25
S5G4T-1	Sol-Gel Technologies	Phase 3	69
S5G4T-1 + S5G4T-2	Sol-Gel Technologies	Phase 3	69
S5G4T-1 + S5G4T-2	Sol-Gel Technologies	Phase 3	69
FMX103 minocycline foam 1.5% + Vehicle foam	Vyne Therapeutics	Phase 3	69
FMX103 1.5%	Vyne Therapeutics	Phase 3	69
FMX103 minocycline foam 1.5% + Vehicle foam	Vyne Therapeutics	Phase 3	69

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved